A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.
What I am trying to establish is why A1C lags the way it does, and what to look at in the meantime if you want to know sooner.
Not looking for reassurance. Looking for the part I have got wrong.
kim_atl_prep said:A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.
My labs after 9 months on glycaemic control: A1C 5.7%, fasting glucose 77 mg/dL, fasting insulin 8 uIU/mL. My endo says these are "textbook perfect."
For context, my baseline A1C was 6.9% and fasting glucose was 132 mg/dL. The improvement has been dramatic and consistent.
PharmD_Rodriguez said:My labs after 9 months on glycaemic control: A1C 5.7%, fasting glucose 77 mg/dL, fasting insulin 8 uIU/mL.
Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 42% to 21%. Target is <36%, with <30% being ideal.
Why this matters more than average glucose: large glucose swings cause oxidative stress, endothelial damage, and promote advanced glycation end-products (AGEs). A flat glucose line at 95 mg/dL is metabolically healthier than oscillating between 60 and 160, even if the average is the same.
Janoshik Analytical — Independent Testing
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesGL Biochem (Shanghai) Ltd. — Direct Manufacturer
Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL Biochemkim_atl_prep said:A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.
Adding a me-too, because a thread of one person's experience is not much use.
From the other side of the consultation, briefly.
Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:
| Test | Baseline | Month 3 | Month 6 | Month 12 |
|---|---|---|---|---|
| Glucose (fasting) | 126 | 100 | 90 | 84 |
| Insulin (fasting) | 22 | 14 | 10 | 7 |
| HOMA-IR | 4.5 | 4.2 | 1.8 | 1.5 |
| Uric Acid | 8.9 | 6.6 | 5.7 | 5.2 |
The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 4.5 to near 1.0 is a metabolic transformation.